- **Q: Why has Oracle's stock price dropped?
**
Yanuki
ARTICLE DETAIL
Is Now the Time to Buy Oracle (ORCL) Stock? | California's Rising Insurance Costs: The Role of Personal Injury Lawyers | Entergy Launches US$2.18 Billion Equity Raise: What It Means for Investors | Tesla (TSLA) Stock Analysis: Challenges and Rebound Potential in 2026 | Mexican Peso Strengthens as Dollar Falls Amid Optimism | Chip Stock Rebound: Is SMH the Best Play? | Dell: Benefiting from the AI Infrastructure Boom | SanDisk Stock: Recent Volatility and Market Sentiment | Rocket Lab's Valuation: Beyond the Launch Story | Is Now the Time to Buy Oracle (ORCL) Stock? | California's Rising Insurance Costs: The Role of Personal Injury Lawyers | Entergy Launches US$2.18 Billion Equity Raise: What It Means for Investors | Tesla (TSLA) Stock Analysis: Challenges and Rebound Potential in 2026 | Mexican Peso Strengthens as Dollar Falls Amid Optimism | Chip Stock Rebound: Is SMH the Best Play? | Dell: Benefiting from the AI Infrastructure Boom | SanDisk Stock: Recent Volatility and Market Sentiment | Rocket Lab's Valuation: Beyond the Launch Story
Finance / Stocks
Is Now the Time to Buy Oracle (ORCL) Stock?
Oracle (ORCL) stock has experienced a significant drop after reaching an all-time high in September 2025, creating a potential entry point for investors. This article examines the factors contributing to the decline and whether current valu...
Key Insights
- Oracle's stock plummeted more than 57% to around $138 per share as of April 11, 2026, due to a broader technology sell-off and investor concerns over capital expenditures.
- The company's Remaining Performance Obligations (RPOs) surged 325% year-over-year, reaching $553 billion in the third quarter of fiscal year 2026.
- Oracle's overall revenue increased 22% year-over-year, with cloud infrastructure revenue jumping 84% to nearly $5 billion.
- Despite high capital expenditure, Oracle reaffirmed its fiscal year 2026 guidance and raised its fiscal year 2027 guidance, projecting revenue of $90 billion.
- The stock's forward price-to-earnings (P/E) ratio is around 18, and the enterprise value-to-EBITDA ratio is approximately 17.5, suggesting a more reasonable valuation than in the fall of 2025.
In-Depth Analysis
Oracle's recent stock performance reflects broader market trends and company-specific factors. The technology sell-off in early 2026 impacted many stocks, including Oracle. However, Oracle's strong cloud growth and massive RPO backlog suggest underlying strength. While the company's financial leverage remains aggressive, its solid liquidity and raised FY2027 revenue guidance support a bullish long-term outlook. Investors should consider Oracle's position in the growing cloud market and its potential for AI-driven growth. The company's current valuation metrics suggest it is more fairly priced than it was previously, making it an appealing option for patient, long-term investors.
FAQ
- **Q: What are Oracle's growth prospects?
**
- **Q: Is Oracle stock currently undervalued?
**
Takeaways
- Oracle's stock decline may present a buying opportunity for long-term investors.
- The company's cloud infrastructure growth and large backlog indicate strong future potential.
- Investors should consider Oracle's valuation metrics and financial health before investing.
Discussion
Do you think Oracle's stock will rebound? Share your thoughts in the comments below! Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.